Browsing by Author "Katz, J."
Now showing 1 - 3 of 3
Results Per Page
Sort Options
Item A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future(Vaccine, 2021) Moore, K.A.; Ostrowsky, J.T.; Kraigsley, A.M.; Mehr, A.J.; Bresee, J.S.; Friede, M.H.; Gellin, B.G.; Golding, J.P.; Hart, P.J.; Moen, A.; Weller, C.L.; Osterholm, M.T.; Ampofo, W.; Barclay, W.; Cavaleri, M.; Cohen, C.; Cowling, B.; Cox, R.; Gust, J.; Innis, B.; Kang, G.; Katz, J.; Krammer, F.; Pitisuttithum, P.; Post, D.; Rudenko, L.; Siqueira, M.; Weir, J.Improved influenza vaccines are urgently needed to reduce the burden of seasonal influenza and to ensure a rapid and effective public-health response to future influenza pandemics. The Influenza Vaccines Research and Development (R&D) Roadmap (IVR) was created, through an extensive international stakeholder engagement process, to promote influenza vaccine R&D. The roadmap covers a 10- year timeframe and is organized into six sections: virology; immunology; vaccinology for seasonal influenza vaccines; vaccinology for universal influenza vaccines; animal and human influenza virus infection models; and policy, finance, and regulation. Each section identifies barriers, gaps, strategic goals, milestones, and additional R&D priorities germane to that area. The roadmap includes 113 specific R&D Abbreviations: ABS, Access and Benefit Sharing; ACT, Access to COVID-19 Tools; ADCC, antibody-dependent cellular cytotoxicity; CARB-X, biopharmaceutical accelerator for combating antibiotic resistant bacteria; CEPI, Coalition for Epidemic Preparedness Innovations; CIDRAP, Center for Infectious Disease Research and Policy; CIVICs, Collaborative Influenza Vaccine Innovation Centers; COBRA, computationally optimized broadly reactive antigen; CHIVIM, controlled human influenza virus infection model; EU, European Union; FVVA, full value of vaccine assessment; GISRS, Global Influenza Surveillance and Response System; HAI, hemagglutination-inhibition; HA, hemagglutinin; HVAC, heating, ventilation, and air conditioning; IIV, inactivated influenza vaccines; IVR, Influenza Vaccines Research and Development (R&D) Roadmap; LAIV, live-attenuated influenza vaccines; LMICs, low- and middle-income countries; ME&A, monitoring, evaluation, and adjustment; NA, neuraminidase; NIAID, US National Institute of Allergy and Infectious Diseases; R&D, Research and Development; SME, subject matter expert; WHO, World Health Organization.Item Strengthening the influenza vaccine virus selection and development process(Elsevier Ltd., 2015-07-03) Ampofo, W.K.; Azziz-Baumgartner, E.; Bashir, U.; Cox, N.J.; Fasce, R.; Giovanni, M.; Grohmann, G.; Huang, S.; Katz, J.; Mironenko, A.; Mokhtari-Azad, T.; Sasono, P.M.; Rahman, M.; Sawanpanyalert, P.; Siqueira, M.; Waddell, A.L.; Waiboci, L.; Wood, J.; Zhang, W.; Ziegler, T.Despite long-recognized challenges and constraints associated with their updating and manufacture, influenza vaccines remain at the heart of public health preparedness and response efforts against both seasonal and potentially pandemic influenza viruses. Globally coordinated virological and epidemiological surveillance is the foundation of the influenza vaccine virus selection and development process. Although national influenza surveillance and reporting capabilities are being strengthened and expanded, sustaining and building upon recent gains has become a major challenge. Strengthening the vaccine virus selection process additionally requires the continuation of initiatives to improve the timeliness and representativeness of influenza viruses shared by countries for detailed analysis by the WHO Global Influenza Surveillance and Response System (GISRS).Item Strengthening the influenza vaccine virus selection and development process. Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014(Vaccine, 2015-08) Ampofo, W.K.; Azziz-Baumgartner, E.; Bashir, U.; Cox, N.J.; Fasce, R.; Giovanni, M.; Grohmann, G.; Huang, S.; Katz, J.; Mironenko, A.; Mokhtari-Azad, T.; Sasono, P.M.; Rahman, M.; Sawanpanyalert, P.; Siqueira, M.; Waddell, A.L.; Waiboci, L.; Wood, J.; Zhang, W.; Ziegler, T.Despite long-recognized challenges and constraints associated with their updating and manufacture, influenza vaccines remain at the heart of public health preparedness and response efforts against both seasonal and potentially pandemic influenza viruses Globally coordinated virological and epidemiological surveillance is the foundation of the influenza vaccine virus selection and development process. Although national influenza surveillance and reporting capabilities are being strengthened and expanded, sustaining and building upon recent gains has become a major challenge Strengthening the vaccine virus selection process additionally requires the continuation of initiatives to improve the timeliness and representativeness of influenza viruses shared by countries for detailed analysis by the WHO Global Influenza Surveillance and Response System (GISRS) © 2015 The Authors.